Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
August 5, 2021 4:05 PM EDT
$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021)
415 patient start forms (PSFs) received for LUPKYNIS during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date
Continued ex-U.S. execution highlighted by the submission of a voclosporin MAA to the EMA by Otsuka
Cash and cash equivalents, and investments of $323.7 million at June 30, 2021
Conference call to be hosted today at 4:30 p.m. EDT
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial... More
